SCHEMBL5137530

SCHEMBL5137530

CCCCN(Cc1ccc(O)c(C(=O)OC)c1)Cc1cnc(-c2ccccc2)n1CCCC

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
KDM4E B2RXH2 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TLR7 Q9NYK1 3/20 0.36
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
TSHR P16473 1/20 0.35
AGTR1 P30556 3/20 0.35
LTB4R2 Q9NPC1 1/20 0.35
PPARG P37231 1/20 0.34
PPARA Q07869 1/20 0.34
C5AR1 P21730 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5135282 0.94 ALDH1A1 (0.37) ALDH1A1HTTSMN1; SMN2KDM4ENPSR1
SCHEMBL5134681 0.91 KAT8 (0.41) KDM4ETSHRAGTR1LTB4R2PPARG
SCHEMBL5137569 0.88 AGTR1 (0.35) ALDH1A1HTTSMN1; SMN2KDM4ENPSR1
SCHEMBL5135175 0.87 AGTR1 (0.43) ALDH1A1SMN1; SMN2KDM4ETLR7AGTR1
SCHEMBL5135275 0.85 LDHA (0.42) TSHRAGTR1LTB4R2C5AR1
SCHEMBL5137555 0.85 HTT (0.42) ALDH1A1HTTSMN1; SMN2NPSR1MEN1
SCHEMBL5135244 0.82 KDM4E (0.35) ALDH1A1HTTKDM4ENPSR1MEN1
SCHEMBL5134636 0.81 AGTR1 (0.46) ALDH1A1KDM4EAGTR1
SCHEMBL5136696 0.81 NPC1 (0.40) ALDH1A1SMN1; SMN2MEN1LMNAKMT2A
SCHEMBL5136085 0.81 AGTR1 (0.45) ALDH1A1SMN1; SMN2KDM4EAGTR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed